Immune regulation in pathophysiology and targeted therapy for itch in atopic dermatitis  by Lee, Chih-Hung
lable at ScienceDirect
DERMATOLOGICA SINICA 34 (2016) 1e5Contents lists avaiDermatologica Sinica
journal homepage: http: / /www.derm-sin ica.comREVIEW ARTICLEImmune regulation in pathophysiology and targeted therapy for itch
in atopic dermatitis
Chih-Hung Lee*
Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwana r t i c l e i n f o
Article history:
Received: Aug 10, 2015
Revised: Oct 5, 2015
Accepted: Oct 16, 2015
Keywords:
atopic dermatitis
IL-31
itch
SALT
TSLPConﬂicts of interest: The author declares that he has
conﬂicts of interest related to the subject matter o
article.
* Corresponding author. Department of Dermatol
Memorial Hospital and Chang Gung University Colleg
Kaohsiung 833, Taiwan.
E-mail address: dermlee@gmail.com.
http://dx.doi.org/10.1016/j.dsi.2015.10.002
1027-8117/Copyright © 2015, Taiwanese Dermatolog
(http://creativecommons.org/licenses/by-nc-nd/4.0/)a b s t r a c t
Itch is an unpleasant perception that provokes one to desire to scratch. It results from the activation of
free nerve endings by noxious stimuli in the skin. Atopic dermatitis (AD) is a prototypic inﬂammatory
skin disease that always occurs with an intense itch. AD involves many components of skin-associated
lymphoid tissue (SALT). As a disease with polarized T helper 2 cell activation, AD involves eosinophil
inﬁltration and immunoglobulin E, interleukin (IL)-2, IL-4, IL-13, and IL-31 production. As a disease
involving an impaired skin barrier, AD is characterized by the enhanced transepidermal entry of al-
lergens and the production of thymic stromal lymphopoietin (TSLP) from epidermal keratinocytes,
which worsen atopic march and disease progression. Both immune and epidermal events interact with
cutaneous nerve components, including transient receptor potential (TRP) channels and opioid re-
ceptors, causing both the perception and propagation of itch from the skin to the brain. In addition to
treating itch through TRP channels and opioid receptors, it might be possible to target the various
cellular components of SALT, including keratinocytes, eosinophils, and soluble factors, such as IL-31, IL-
4, IL-13, IL-31, and TSLP.
Copyright © 2015, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Atopic dermatitis (AD) is a common chronic relapsing disease
with intense itch. AD usually accompanies a personal or familial
history of allergic diseases, including allergic rhinitis, asthma, and
allergic conjunctivitis.1 Itch is the cardinal symptom of AD. It
severely interferes with the life quality of patients and their
caregivers and it may impair school and work performance and
trigger anxiety and depression.2 The prevalence of AD is esti-
mated to be 6e9% in Taiwan.3 While the exact pathogenesis of AD
remains to be investigated, both impairment of the skin barriers
and aberrant immune activation play signiﬁcant roles in its
pathogenesis.4,5no ﬁnancial or non-ﬁnancial
r materials discussed in this
ogy, Kaohsiung Chang Gung
e of Medicine, 123 Dapi Road,
ical Association. Published by Els
.Itch perception: From skin initiation to brain activation
Itch is a unique perception that provokes one to desire to scratch to
get rid of noxious stimuli.6 Cough, which may be induced by
noxious chemicals or particles, is a similar action used to expel such
stimuli. The epidermis is innervated by small unmyelinated C ﬁber.
The perception of itch is transmitted from the peripheral free nerve
endings (C ﬁber) in the epidermis back to the neuron body in the
dorsal root ganglion located at the spinal cord. Subsequently, a
synapse in the spinal cord transmits the signal in the contralateral
spinothalamic tract to the thalamus, and eventually the signal ra-
diates to the cortical neurons.7
In skin, the propagation of itch could result from both inﬂam-
matory and noninﬂammatory diseases. AD is a prototypic inﬂam-
matory skin disease that is always accompanied by intense itching.8
People affected by other inﬂammatory skin diseases, such as lupus
erythematosus and pityriasis lichenoides, may or may not experi-
ence itch. Among the noninﬂammatory skin diseases, some dis-
eases (e.g., uremic pruritus) may cause itch, but others (e.g., stable
vitiligo) may not. In diseases with inﬂammatory conditions, im-
mune factors may play a signiﬁcant role in the initiation of itch. Onevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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neurogenic factors may play a more signiﬁcant role in itch
pathophysiology.
Several functional imaging studies have been performed to
observe the functional activation of itch signals in the brain.
However, different diseases associated with itching can cause dif-
ferences in the activation of the brain cortex. Furthermore,
histamine-induced or non-histamine-induced itch causes differ-
ences in the chronological and topological activation of the brain
cortex.9 Based on the principle of near-infrared spectroscopy, one of
our previous studies demonstrated that brain cortex activation,
reﬂected by changes in oxygenated and deoxygenated hemoglobin
levels, in histamine-induced itch is distinctly different from
pushepull gauge-induced pain.10
Impaired skin barrier and itch perception
AD is characterized by the impairment of the skin barrier. The
epidermis is an intact tissue that protects the human body from
harsh outside environments and is fully organized with ordered
differentiated keratinocytes and has a densely packed corneal layer
equipped with “brick and mortar.” However, the impaired skin
barrier in AD allows the entry of potential allergens, which subse-
quently aggravate the inﬂammatory responses and thereby further
deteriorate the impaired skin barrier, creating a vicious cycle.11
Filaggrin, an important protein that binds to keratins associated
with keratinocyte differentiation, is important to the integrity of
the skin barrier. In AD, approximately half of the patients are
affected by the mutations in ﬁlaggrin.12 The loss or mutation of
ﬁlaggrin, which decreases the skin's ability to hold water, impairs
skin barrier function. On the other hand, enhancing the barrier
function of the skin increases the therapeutic effects on AD.13 We
previously found an association between barrier dysfunction, an
increase in transepidermal water loss (TEWL), and itch intensity.14
The greater the TEWL, the worse the itch. In fact, increased TEWL
has been positively correlated with an increase in skin pH, pro-
moting the activity of serine proteases to their disruption of the
skin barrier and inducing pruritus.15
Skin-associated lymphoid tissue
Before we discuss the role of aberrant immune responses in the
pathophysiology of AD, the topic of skin-associated lymphoid tissue
(SALT) needs to be reviewed. In the gastrointestinal tract, lymphoid
structures are present in some submucosal areas, which are also
referred to as mucosa-associated lymphoid tissue (MALT).16 MALT
is specialized in the appropriate antigen presentation indepen-
dently of the secondary lymphoid organs (lymph nodes). This is
evidenced by the fact that MALT lymphoma can derive directly
from several gastrointestinal mucosal tissues, independently of its
associated lymph nodes. Noting similarities in antigen presentation
and T cell trafﬁcking from skin to lymph nodes, Streilein et al17
introduced the term “skin-associated lymphoid tissue” (SALT) and
proposed that SALT acts as an integrated immunosurveillance sys-
tem for the skin. Like MALT lymphoma, SALT by itself can develop
several cutaneous lymphomas with different lymphoid cell origins
independent of the lymph nodes. SALT is comprised of: (1)
epidermal Langerhans cells; (2) T cells; (3) keratinocytes; and (4) a
set of draining lymph nodes, along with endothelial cells and
several dermal cells.18 Ono and Kabashima19 proposed the term
“inducible SALT” as they found that the interleukin (IL)-1a pro-
duced by keratinocytes activated perivascular macrophages, which
attracted dermal dendritic cells via CXCL2 signaling under an in-
ﬂammatory condition in a model of contact dermatitis. We then
discuss the role of several lineages of immune cells of SALT in thepathophysiology of itch in AD, a proinﬂammatory disease with
dynamic innate and adaptive immune responses.
Role of cellular and soluble components of SALT in AD
Eosinophils
The association between eosinophil inﬁltration and itch perception
is well known with regard to scabies infestation.20 Patients with
scabies experience intense itching, and their skin is densely inﬁl-
trated by eosinophils. Patients with bullous pemphigoid also
experience a signiﬁcant itch and have moderate eosinophil-rich
dermal inﬂammation. Eosinophil-deﬁcient mice (PHIL mice) have
impaired hapten-induced hypersensitivity responses, reduced
scratching behavior, and decreased PGP9.5 stained nerve endings.21
However, there remains some debate as towhether eosinophils and
itch might have just a serendipitous relationship via the in-
teractions of immunoglobulin E (IgE) and mast cells.20
Fibroblasts
Keloid scarring occurs with a proliferation of ﬁbroblasts and an
unregulated deposition of extracellular matrix, and there is often
intense itch as the disease progresses.22 Keloid skin scars havemore
nerve ﬁbers. It has also been noted that dermal ﬁbroblasts secrete
artemin, a neurotrophic factor, in response to substance P and that
these artemin-expressing ﬁbroblasts are increased in AD skin.23
Keratinocytes
The extent of skin innervations depend on the balance between
nerve elongation factors [e.g., nerve growth factor (NGF)] and nerve
repulsion factors (e.g., semaphorin 3A), both of which can be pro-
duced by epidermal keratinocytes. The blood concentration of NGF
correlates well to itch intensity in patients with AD, while
epidermal semaphorin 3A levels are low in AD patients who also
have increased epidermal nerve density.24 Furthermore, in a pre-
vious study of keratinocytes, we found that IL-31 induces stromal
interaction molecule 1 (STIM1) activation, signal transducer and
activator of transcription 3 (STAT3) phosphorylation, and beta-
endorphin release,25 and in another study, we found that the
blood levels of beta-endorphins correlate well to subjective itch
intensity.14
Thymic stromal lymphopoietin (TSLP), another cytokine pro-
duced by keratinocytes, plays an important role in the patho-
physiology of AD. Expression of TSLP is increased in keratinocytes
in AD. TSLP contributes to the progression of atopic march in a
variety of disorders ranging from the sensitization of AD in skin to
the development of asthma and other allergic diseases.26 In mice,
overexpression of TSLP induces AD-like skin.27 Keratinocyte
signaling through TSLP to immune cells may play an important role
in AD. Keratinocyte-derived TSLP directly activates cutaneous
sensory neurons to promote itch perception.28 In fact, the signaling
from the Ca2þ release-activated Ca2þ channel (ORAI1), which in-
teracts with STIM1 in the cell membrane of keratinocytes, can
induce the production of TSLP, which then activates transient re-
ceptor potential cation channel, subfamily A, member 1 (TRPA1)
and thereby induces itch.28 Undoubtedly, keratinocytes play a
pivotal role in the initiation of itch. In fact, one of our previous
international studies found an association between the genetic
predisposition of ORAI1 and the development of AD. That study
found an association between the single gene polymorphism of
ORAI1, a calcium channel protein, and the development and
severity of AD in both Japanese and Taiwanese populations.29
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Histamine is a well-known pruritogen released from mast cells in
response to IgE crosslinking and degranulation in urticaria. It might
be possible to use traditional antihistamines to target H1 or H2
receptors when treating itch associated with a variety of diseases,
but itch accompanying AD is probably unrelated to histamine
because it is not satisfactorily relieved by anti-H1 and anti-H2
histamine. Further efforts, however, have been made to target
another histamine receptor, H4R, to treat itch. A phase 2a study in
Japan demonstrated that the H4 antagonist (JNJ-39758979) allevi-
ates itch in patients with AD.30 In addition, the use of omalizumab
as an anti-IgE agent reduces the clinical severity of AD in patients
with very high IgE, suggesting that the therapeutic beneﬁt of anti-
IgE results not only from the neutralization of IgE but also from the
downregulation of high-afﬁnity IgE-Fc receptors on basophils and
mast cells.31
T cells and cytokines
IL-2
High-dose IL-2, which has been used as an immunotherapy agent
against metastatic renal cell carcinoma and malignant melanoma,
induces severe itch.32 Injection of IL-2 into healthy controls or into
patients with AD induces a 48e72 hour itch. Cyclosporin, a calci-
neurin inhibitor, decreases the synthesis of IL-2 and reduces itch in
patients with AD.33 However, whether the antipruritic effects of
cyclosporin are mediated via its decrease of IL-2 or via its other
immunosuppressive effects in AD remains controversial.
IL-31
The transgenic overexpression of the cytokine IL-31 in lymphocytes
induces severe pruritus and atopic-like dermatitis in mice.34 IL-31,
expressed preferentially in T helper 2 (Th2) cells, activates a het-
erodimeric receptor composed of IL-31 receptor A (IL-31RA) and
oncostatin M receptor in keratinocytes and nerve endings.35 The
blood levels of IL-31 are increased in many patients with pruritic
skin diseases, including AD, cutaneous T cell lymphoma, uremic
pruritus, chronic urticaria, and prurigo nodularis.36 Increased ex-
pressions of IL-31RA and IL-31 are observed in the epidermis of
patients with AD.37 Furthermore, the blood level of IL-31 is corre-
lated to disease severity in patients with AD.36 Consistent with
these ﬁndings, IL-31 induces the activation of STIM1, followed by
the activation of STAT3 and the release of beta-endorphins from
keratinocytes in peripheral skin.25 In the central processing of itch,
dorsal root ganglion neurons co-express TRPV1 and IL-31R.38 IL-31-
induced itch requires TRPV1 and TRPA1.38 Interestingly, IL-31 de-
lays the onset of pruritus by hours, suggesting that the itch in-
duction by IL-31 may occur through an indirect mechanism rather
than through cutaneous receptor activation.39 Together, these
ﬁndings suggest that IL-31 may be targeted in the treatment of itch.
In fact, a Phase 1 clinical trial is being conducted to test the effect of
anti-IL-31 antibody (NCT01614756).40
IL-4 and IL-13
The receptors of IL-4 and IL-13 have a common subunit. As Th2
cytokines, IL-4 and IL-13 are important in the development of AD.
The transgenic overexpression of IL-4 or IL-13 in mice causes a
severely itchy atopic disease-like phenotype.41 IL-4 and IL-13 are
increased in AD skin. In blood, the level of IL-13 is increased in AD
and correlated with disease severity.42 A mouse study showed that
IL-13 induces pruritus in AD at least in part through the activation
of TRPA1.43 Treatment with the monoclonal antibody against IL-4,
dupilumab, reduces itch perception in AD by more than half.44 Insummary, both cytokines may mediate the development of itch to
some extent.
Nerve components in itch perception
Transient receptor potential channels
Transient receptor potential (TRP) channels, expressed in various
cells, including keratinocytes, melanocytes, and nerves in the skin,
may act in sensory processing and other biological functions.45
Several classes of TRP proteins, including TRPV1, TRPA1, and
TRPM8, are implicated in itch.46
TRPV1 expression is increased in AD skin lesions, and its acti-
vation promotes both immune responses and itch by secreting
soluble factors.47 Amagai et al48 reported that in conventional NC/
Tnd mice with AD, TRPV1 stimulation reduces scratching behavior,
and suggested that it might be used as a TRPV1 modulator in the
treatment of atopic itch. However, one recent clinical trial investi-
gating the effects of topical TRPV1 inhibitor (SB705498) failed to
demonstrate its efﬁcacy on the relief of itch induced by histamine
or cowhage.49
TRPA1 is a known transducer of histamine-independent itch.50
It is present in sensory nerves, mast cells, and keratinocytes.51,52
TRPA1, which is increased in AD, mediated pruritus in an IL-13-
induced AD model.52 However, the biological effects of TRPA1 on
the itch of AD are complicated. On the one hand, TRPA1 transduces
itch signals; on the other hand, its activation promotes barrier re-
covery.53 As mentioned above, IL-31-mediated itch requires TRPV1
and TRPA1.38
TRPM8 is expressed in both A-delta ﬁbers and C ﬁbers.54,55
Administration of substance P attenuates the scratching activity
induced bymenthol, a TRPM8 agonist.46 In a subset of patients, itch
is transmitted through A-delta ﬁbers but not commonly through
unmyelinated C ﬁbers.56 The different components of nerve ﬁbers
might explain the diversity of the itch that patients experience.56
Opioid receptors
Morphine, a strong analgesic, induces or enhances itch in a signif-
icant portion of healthy individuals. However, m-opiate receptor
antagonists inhibit itch but not pain. One of our previous studies
found an association between the blood levels of beta-endorphins
and itch intensity in patients with AD.14 Morphine-induced itch
may be related to the fact that morphine binds to the m-opioid
receptor isoform MOR1D, which heterodimerizes with the gastrin-
releasing peptide receptor coexpressed in itch-signaling spinal
neurons.57 The k-agonist TRK-820 (nalfuraﬁne) inhibits pruritogen-
evoked scratching,58 suggesting that the k-opioid receptor may
play a putative role in the modulation of itch. TRK-820 has been
proven effective in relieving intractable itch in patients on renal
dialysis.59
Treatment strategy for alleviating inﬂammation and itch
Physicians have known for many years that antihistamines barely
alleviate itch in patients with AD with active itching. A burst use of
systemic steroid, which abolishes the most upstream cause of
inﬂammation, is particularly useful in controlling the acute ﬂare
and itch of AD. In the subacute phase, the calcineurin inhibitor
cyclosporin is also helpful in controlling inﬂammatory itch. Many
monoclonal biologics are being developed or have been developed
to treat inﬂammation-related itch in AD (Table 1). To name a few,
dupilumab, a monoclonal antibody against IL-4, markedly and
rapidly improves itching in AD patients,44 and the monoclonal
antibody against IL-13, lebrikizumab, for which an AD trial is
Table 1 Potential targets in the treatment of inﬂammation-related itch in atopic
dermatitis.
Target Clinical trial Compound Phase Company
IL-31 NCT01614756 BMS-981164 I Bristol-Myers Squibb
IL-4 NCT01979016 dupilumab II Regeneron
IL-22 NCT01941537 ILV-094 II Rockefeller University
IL-13 NCT02340234 lebrikizumab II Roche
NCT02347176 tralokinumab IIb MedImmune LLC
TSLP NCT00757042 AMG 157 I/II Amgen
IgE NCT02148744 XmAb7195 I Xencor
NCT01544348 MEDI4212 I MedImmune LLC
IgE ¼ immunoglobulin E; TSLP ¼ thymic stromal lymphopoietin.
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promise in the treatment of asthma.60
Conclusions
The itch in AD always occurs concurrently with inﬂammation and
the desire to scratch. This vicious cycle of scratch, inﬂammation,
and itch make the itch associated with AD a troublesome clinical
problem. Any of the components discussed in this review could be
interrupted to treat itch or its associated inﬂammation in AD. The
delicate regulation of the various components of SALT leads to the
dynamic homeostasis of immune responses in skin. Studies tar-
geting the components of SALT, including keratinocytes, eosino-
phils, and soluble factors, such as IL-31, IL-4, IL-13, and TSLP, might
shed new light on the development of treatment strategies for in-
ﬂammatory itch in AD.
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